JAK Inhibitors Show Efficacy Across Inflammatory Skin Diseases in 15,427-Patient Analysis
Key Clinical Summary
· Broad efficacy: JAK inhibitors demonstrated clinical efficacy across multiple inflammatory skin diseases, including atopic dermatitis, psoriasis, alopecia areata, and vitiligo, in an analysis of 68 studies involving 15,427 patients.
· Safety considerations: Upper respiratory infections and herpes zoster reactivation occurred more frequently with JAK inhibitors than placebo, while major cardiovascular events, venous thromboembolism, and cancers were rare but reported.
· Treatment selection: Selective JAK1 inhibitors appeared to offer the most favorable efficacy-safety balance for atopic dermatitis, while JAK1/2 inhibitors showed numerically greater efficacy for alopecia areata without reaching statistical significance.
Janus kinase (JAK) inhibitors demonstrated efficacy across several inflammatory skin diseases, although questions remain about long-term safety and comparative effectiveness, according to a systematic review and meta-analysis encompassing 15,427 patients.
Study Findings
The analysis, published online in Clinical Drug Investigation, included 68 studies evaluating JAK inhibitors for atopic dermatitis (AD), psoriasis, vitiligo, alopecia areata (AA), and hidradenitis suppurativa. Researchers assessed 42 randomized controlled trials, 14 open-label extensions, and 12 real-world cohort studies.
Oral JAK inhibitors produced responses across multiple diseases compared with placebo. Eczema Area and Severity Index 75% improvement response rates ranged from 38% to 73% among patients with AD. Psoriasis Area and Severity Index 75% improvement rates ranged from 33% to 67% in psoriasis, while Severity of Alopecia Tool 50% improvement rates ranged from 30% to 62% in AA.
Topical JAK inhibitors were effective for AD and vitiligo but demonstrated limited benefit in AA.
Clinical Implications
Selective JAK1 inhibitors appeared to provide the most favorable efficacy-safety balance for AD. JAK1/2 inhibitors showed numerically greater efficacy for AA, although the difference was not statistically significant.
Safety profiles were generally similar among the evaluated therapies. Upper respiratory infections occurred in 5% to 14% of patients, and herpes zoster reactivation occurred in 1% to 3%, with both reported at higher rates than placebo. Major cardiovascular events, venous thromboembolism, and cancers were rare but occurred during treatment.
Expert Commentary
The authors concluded that JAK inhibitors demonstrate “significant efficacy across several inflammatory skin diseases,” while emphasizing that their safety profile “warrants ongoing monitoring, particularly in patients with cardiovascular risk factors.”
They cautioned that long-term conclusions remain limited by short controlled-trial durations, under-representation of diverse populations, and reliance on indirect comparisons.
Reference
Zayed NF, Seetan K, Khamees A, Yassin RY, Ba-Shammakh SA. JAK inhibitors in inflammatory skin diseases: a 15,427-patient systematic review and meta-analysis of clinical trial and real-world outcomes. Clin Drug Investig. Published online July 14, 2026. doi:10.1007/s40261-026-01583-7
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Dermatology Learning Network or HMP Global, their employees, and affiliates.
Related Content
Where Dermatology NPs and PAs Learn, Lead, and Level Up.
The Derm NP/PA is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The Derm NP/PA is designed for advanced practice providers who specialize in dermatology to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods while remaining focused on the fundamental principles and terminology associated with dermatology. Engage year-round with The Derm NP/PA to access clinical insights, interactive features, research news updates, accredited continuing-education programs, and more.
